- Home
- ABSI vs DCTH Comparison
ABSI vs DCTH Comparison
Compare ABSI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- DCTH
- Stock Information
- Founded
- ABSI 2011
- DCTH 1988
- Country
- ABSI United States
- DCTH United States
- Employees
- ABSI N/A
- DCTH N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- ABSI Health Care
- DCTH Health Care
- Exchange
- ABSI Nasdaq
- DCTH Nasdaq
- Market Cap
- ABSI 338.0M
- DCTH 388.3M
- IPO Year
- ABSI 2021
- DCTH N/A
- Fundamental
- Price
- ABSI $2.62
- DCTH $10.67
- Analyst Decision
- ABSI Strong Buy
- DCTH Strong Buy
- Analyst Count
- ABSI 5
- DCTH 4
- Target Price
- ABSI $7.98
- DCTH $24.50
- AVG Volume (30 Days)
- ABSI 4.1M
- DCTH 485.5K
- Earning Date
- ABSI 11-11-2025
- DCTH 11-07-2025
- Dividend Yield
- ABSI N/A
- DCTH N/A
- EPS Growth
- ABSI N/A
- DCTH N/A
- EPS
- ABSI N/A
- DCTH 0.06
- Revenue
- ABSI $4,138,000.00
- DCTH $70,240,000.00
- Revenue This Year
- ABSI $44.71
- DCTH $159.22
- Revenue Next Year
- ABSI $374.26
- DCTH $41.22
- P/E Ratio
- ABSI N/A
- DCTH $193.75
- Revenue Growth
- ABSI 27.32
- DCTH 491.35
- 52 Week Low
- ABSI $2.01
- DCTH $8.08
- 52 Week High
- ABSI $6.33
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- ABSI 49.98
- DCTH 43.30
- Support Level
- ABSI $2.37
- DCTH $10.60
- Resistance Level
- ABSI $2.89
- DCTH $11.38
- Average True Range (ATR)
- ABSI 0.15
- DCTH 0.44
- MACD
- ABSI 0.03
- DCTH 0.01
- Stochastic Oscillator
- ABSI 52.63
- DCTH 5.26
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.